The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Arrinex, Inc. operates as a funded medical device company. It develops medical procedure that is used in patients with refractory chronic rhinitis. The firm develops disruptive cryotherapy technology for treating chronic nasal allergy symptoms: congestion and drainage. The company was founded by Vahid Saadat and Mojgan Saadat and is headquartered in Redwood City, CA.

Neurovalens Ltd. provides solutions in the field of neuroscience, bioscience, and neurophysiology. It develops Modius a non-invasive, drug-free device that uses a safe method of stimulation to activate the vestibular system and help you achieve a leaner body when used n conjunction with a healthy diet and appropriate levels of exercise. The company was founded by Paul McGeoch and Jason McKeown in 2013 and is headquartered in Belfast, the United Kingdom.

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

DIO Corp. engages in the manufacture and sale of medical devices. Its products include dental implants, toothpastes, dentistry equipment, and stents. The company was founded on January 25, 1988 and is headquartered in Busan, South Korea.

NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma is focused on commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I, II, & III clinical trials.

Orsan Medical Technologies Ltd. is a private company headquartered in Netanya, Israel. The firm develops a non-invasive and automatic device to measure and monitor cerebral blood flow.

SPRA Therapeutics is a medical device company that is commercializing pain treatments utilizing its proprietary peripheral nerve stimulation (PNS) products. They are developing a pipeline of neurostimulation pain therapies that will exploit the same physiologic mechanism of action, proprietary technology, and clinical approach. The first product to be commercialized is the SMARTPATCHâ„¢ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain.

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Stratus Medical is a medical device company focused on reducing pain and suffering and improving the quality of life for chronic pain patients through innovation. Our leading product is the Nimbus RF Multitined Expandable Electrode that was developed to address the unmet need for an easy to use, efficient, cost-effective RF device that provides a large volume and optimally shaped lesion, which interventional pain specialists, orthopedic surgeons and neurosurgeons can use to treat pain. Nimbus has been shown to reduce procedural time and increase efficiency for hospitals and surgery centers where Nimbus is utilized. The Nimbus device is FDA cleared and CE marked. Nimbus has been utilized in over 100,000 patient treatments in Australia, Brazil, Canada, United Kingdom, United States and other countries.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™ therapy, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology, and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

Fempulse is a high tech company that manufactures a small subset of products aimed at combating overactive bladder syndrome.

Relievant Medsystems, Inc. develops treatment and technologies for chronic back pain. Its Intracept System solution is a minimally invasive procedure that uses radiofrequency energy delivered into the vertebral body of the spine to ablate the basivertebral nerve. Relievant Medsystems was founded by James C. Peacock, Jeffrey Charles Lotz, and Rex Peters in 2004 and is headquartered in Redwood City, CA.

Medtronic Xomed, Inc. manufactured and distributed surgical products. It offered powered tissue-removal systems, microendoscopy instruments, implantable devices, nerve monitoring systems, disposable fluid-control metal, and image-guided surgery system products. The company was headquartered in Jacksonville, FL.

Incept is an effective vehicle for promotion and advancement of technology innovation and entrepreneurship with a primary focus in the life-sciences space, and occasional involvement in unique and select information-technology opportunities, where Incept’s management and financing depth is found to be transferable to the IT space. Incept’s mission is to innovate leadership product lines, meeting the important unmet technological needs of the medical technology space while cultivating leaders who build superb companies focused on growth and creation of shareholder value.

Tulavi Therapeutics is a biotechnology company that is dedicated to developing new therapies to treat neurally mediated diseases. The company's solution is dedicated to developing therapies that directly target the nerves to prevent and/or treat aberrant neural reflex arcs in the peripheral and visceral disease that can be administered through surgical and interventional approaches, enabling physicians to treat such diseases in a better way. The company was founded in 2018 and is headquartered in Mountain View, California.